Supernus Pharmaceuticals, Inc.

SUPN Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of SUPN by members of U.S. Congress

Politician Type Traded
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Oct 09, 2025
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Mar 24, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec 23, 2022
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Nov 13, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Jul 17, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Jun 01, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 May 28, 2020
SUPN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
SUPN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SUPN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in SUPN holdings by institutional investors

Insider Trading

Quarterly net insider trading by SUPN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $20,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Sep 25, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Jul 18, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Apr 15, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Oct 17, 2024 Issue: Medicare/Medicaid Health Issues
  • $20,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
  • $20,000 Apr 17, 2024 Issue: Medicare/Medicaid Health Issues
  • $20,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Feb 07, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Oct 19, 2022 Issue: Medicare/Medicaid Health Issues
Corporate Lobbying

SUPN Estimated quarterly lobbying spending

Revenue Breakdown

SUPN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
SUPN Income Statement
SUPN Balance Sheet
SUPN Cash Flow
U.S. Patents

New SUPN patent grants

  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jan. 02, 2018
  • Patent Title: Methods of producing molindone and its salts Oct. 31, 2017
  • Patent Title: Method of treatment of aggression Oct. 31, 2017
  • Patent Title: Topiramate compositions and methods of enhancing its bioavailability Aug. 29, 2017
  • Patent Title: Formulations of viloxazine May. 30, 2017
  • Patent Title: Sustained-release formulations of topiramate Apr. 18, 2017
  • Patent Title: Formulations of viloxazine Mar. 28, 2017
  • Patent Title: Osmotic drug delivery system Feb. 14, 2017
  • Patent Title: Methods of producing molindone and its salts Feb. 07, 2017
  • Patent Title: Sustained-release formulations of topiramate Jan. 31, 2017
  • Patent Title: Sustained-release formulations of topiramate Jan. 24, 2017
  • Patent Title: Viloxazine compositions Sep. 06, 2016
  • Patent Title: Methods for producing viloxazine salts and novel polymorphs thereof Aug. 02, 2016
  • Patent Title: Osmotic drug delivery system Jul. 19, 2016
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jun. 21, 2016
  • Patent Title: Formulations of viloxazine Jun. 07, 2016
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof May. 31, 2016
  • Patent Title: Less abusable pharmaceutical preparations Apr. 12, 2016
  • Patent Title: Drug formulations having reduced abuse potential Sep. 29, 2015
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 01, 2015
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 01, 2015
  • Patent Title: Sustained-release formulations of topiramate Mar. 31, 2015
  • Patent Title: Methods of producing molindone and its salts Feb. 17, 2015
  • Patent Title: Drug formulations having reduced abuse potential Dec. 09, 2014
  • Patent Title: Sustained-release formulations of topiramate Nov. 18, 2014
  • Patent Title: Sustained-release formulations of topiramate Nov. 04, 2014
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 02, 2014
  • Patent Title: Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics Aug. 19, 2014
  • Patent Title: Stabilized formulations of cns compounds Jun. 10, 2014
  • Patent Title: Osmotic drug delivery system Jun. 10, 2014
  • Patent Title: Once daily formulations of tetracyclines Apr. 29, 2014
  • Patent Title: Compositions of quaternary ammonium compounds containing bioavailability enhancers Apr. 29, 2014
  • Patent Title: Sustained-release formulations of topiramate Mar. 04, 2014
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Dec. 31, 2013
  • Patent Title: Controlled release compositions of gamma-hydroxybutyrate Dec. 03, 2013
  • Patent Title: Once daily formulations of tetracyclines Jun. 25, 2013
  • Patent Title: Once daily formulations of tetracyclines Mar. 12, 2013
  • Patent Title: Once daily formulations of tetracyclines Mar. 12, 2013
  • Patent Title: Sustained-release formulations of topiramate Oct. 30, 2012
  • Patent Title: Sustained-release formulations of topiramate Oct. 30, 2012
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jul. 03, 2012
  • Patent Title: Once daily formulations of tetracyclines Jun. 26, 2012
  • Patent Title: Controlled release compositions of gamma-hydroxybutyrate Jun. 05, 2012
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 13, 2011
  • Patent Title: Method of treating seizures using modified release formulations of oxcarbazepine Mar. 22, 2011
  • Patent Title: Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics Mar. 22, 2011
  • Patent Title: Trospium chloride treatment method Aug. 24, 2010
  • Patent Title: Once daily dosage forms of trospium Aug. 24, 2010
  • Patent Title: Method of treating bladder dysfunction with once-a-day trospium salt formulation Jul. 20, 2010
  • Patent Title: Once daily formulations of tetracyclines Jul. 06, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to SUPN from public contracts

SUPN News

Recent insights relating to SUPN

CNBC Recommendations

Recent picks made for SUPN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SUPN

SUPN Analyst Ratings

SUPN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
SUPN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $SUPN stock a Buy, Sell, or Hold?

  • What is the price target for $SUPN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

SUPN Top Shareholders
Shareholder
Shares Held
SUPN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $SUPN stock?

  • Who owns the most shares of $SUPN stock?

  • What funds own $SUPN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

SUPN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SUPN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About SUPN

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

  • Address Rockville, MD
  • Market Cap 2.6 billion
  • Employees 674
  • Industrial Classification Pharmaceutical Preparations
Back To Top